Tech Company M&A Transactions
Zystor Therapeutics Acquisition
On 8/17/2010, Zystor Therapeutics was acquired by BioMarin Nederland B.V.. BioMarin Nederland B.V. said the transaction price was $115 million.
Transaction Overview
Company Name
Acquired By
Announced On
8/17/2010
Transaction Type
M&A
Amount
$115,000,000
M&A Terms
Under the terms of the agreement, BioMarin acquired ZyStor for $22 million upfront and up to an additional $93 million if certain development, regulatory and commercial milestones are achieved.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
10437 Innovation Drive 100
Milwaukee, WI 53226
USA
Milwaukee, WI 53226
USA
Phone
Website
Email Address
Overview
ZyStor Therapeutics, Inc. is a biotechnology company developing innovative therapeutics that will significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
George Arida
Chief Executive Officer
Loren Peterson
Chief Scientific Officer
Jonathan LeBowitz
Browse more venture capital transactions:
Prev: 8/17/2010: Servio venture capital transaction
Next: 8/17/2010: IGA Worldwide venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs